CJC-1295 & Ipamorelin Blend (10mg)

Description

Buy CJC-1295 Ipamorelin Blend – Research Compound

Overview

Buy CJC-1295 Ipamorelin Blend, a dual peptide blend studied for its potential to support growth hormone signaling through complementary pathways. While both compounds are classified as growth hormone secretagogues, they act on different receptors, making this combination a popular choice in advanced research environments.

CJC-1295 Ipamorelin for Sale here is designed to mimic the natural growth hormone-releasing hormone (GHRH), targeting receptors in the anterior pituitary. Ipamorelin, on the other hand, interacts with ghrelin-related receptors (GHS-R1a), offering a more selective signaling pathway.

Together, this blend is often explored for its potential to create a more sustained and coordinated growth hormone response.

Why This Blend Stands Out

• Dual-pathway stimulation (GHRH + GHS receptors)
• Short-term and extended signaling potential
• Designed for enhanced pharmacokinetic stability
• Widely studied in GH and IGF-1 related research

Mechanism Insights

CJC-1295 Ipamorelin for Sale here is a modified version of GHRH (1-29) engineered for improved stability and longer activity. Its structure allows it to remain active in plasma for extended periods, supporting prolonged signaling.

Ipamorelin is a selective pentapeptide that binds to ghrelin receptors and may initiate growth hormone release without significantly affecting other pituitary hormones.

In combination:

• Ipamorelin may trigger early-phase signaling
• CJC-1295 may sustain and extend the response

Chemical Profile

• CJC-1295 Molecular Formula: C152H252N44O42
• Molecular Weight: 3367.9 g/mol
• Also Known As: Mod GRF 1-29
• Ipamorelin Molecular Formula: C38H49N9O5
• Molecular Weight: 711.8 g/mol
• Also Known As: NNC 26-0161

Research Highlights

• Ipamorelin demonstrates a short activity window (~2 hours), making it suitable for initial signaling phases
• CJC-1295 has been observed in plasma for extended durations, with potential activity lasting several days
• Studies suggest increases in growth hormone pulsatility and IGF-1 signaling
• Combination research indicates a complementary effect due to different receptor pathways

Applications in Research

• Growth hormone pathway studies
• IGF-1 and metabolic signaling research
• Endocrine system investigations
• Peptide synergy and pharmacokinetics